0001104659-18-033271.txt : 20180515
0001104659-18-033271.hdr.sgml : 20180515
20180515091738
ACCESSION NUMBER: 0001104659-18-033271
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180412
FILED AS OF DATE: 20180515
DATE AS OF CHANGE: 20180515
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: ROSENBERG MORRIS
CENTRAL INDEX KEY: 0001202786
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-12104
FILM NUMBER: 18833491
MAIL ADDRESS:
STREET 1: C/O SAETTLE GENETICS INC
STREET 2: 21823 30TH DRIVE SE
CITY: BOTHELL
STATE: WA
ZIP: 98021
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: IMMUNOMEDICS INC
CENTRAL INDEX KEY: 0000722830
STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
IRS NUMBER: 611009366
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0630
BUSINESS ADDRESS:
STREET 1: 300 AMERICAN RD
CITY: MORRIS PLAINS
STATE: NJ
ZIP: 07950
BUSINESS PHONE: 9736058200
MAIL ADDRESS:
STREET 1: 300 AMERICAN ROAD
CITY: MORRIS PLAINS
STATE: NJ
ZIP: 07950
3
1
a3.xml
3
X0206
3
2018-04-12
0
0000722830
IMMUNOMEDICS INC
IMMU
0001202786
ROSENBERG MORRIS
C/O IMMUNOMEDICS, INC
300 THE AMERICAN ROAD
MORRIS PLAINS
NJ
07950
0
1
0
0
See Remarks
Stock Options (right to buy)
8.70
2024-06-29
Common Stock, par value $0.01 per share
22500
D
Stock Options (right to buy)
15.68
2025-01-08
Common Stock, par value $0.01 per share
27027
D
Stock Options (right to buy)
15.68
2025-01-08
Common Stock, par value $0.01 per share
77362
D
The reporting person was granted performance-based vesting stock options pursuant to the Company's 2014 Long-Term Incentive Plan. The stock options will vest (i) 1/3 on the first anniversary of the grant date, (ii) 1/3 on the successful filing and acceptance by the FDA for accelerated approval of the BLA for TNBC and (iii) 1/3 on the approval by the FDA of the BLA for TNBC.
The reporting person was granted stock options pursuant to the Company's 2014 Long-Term Incentive Plan. The stock options vest 25% on the first anniversary of the date of grant and 2.08333% on a monthly basis thereafter.
The reporting person was granted performance-based vesting stock options pursuant to the Company's 2014 Long-Term Incentive Plan. The stock options will vest (i) as to 38,866 shares (a) 25% on the first anniversary of the date of grant and 2.08333% on a monthly basis thereafter through the fourth anniversary of the date of grant (each date a "Vesting Date") and (b) subject to Immunomedics, Inc. common stock achieving a fair market value of $31.36 or higher based on the average closing price for the prior 15 consecutive trading days on such Vesting Date; and (ii) as to 38,496 shares (a) 25% on the first anniversary of the date of grant and 2.08333% on a monthly basis thereafter through the fourth anniversary of the date of grant and (b) subject to Immunomedics, Inc. common stock achieving a fair market value of $47.04 or higher based on the average closing price for the prior 15 consecutive trading days on such Vesting Date.
If the performance-based vesting criteria of the stock options is not attained on an applicable Vesting Date, and to the extent such performance-based vesting criteria is subsequently attained, the applicable tranche of stock options may vest on the date such criteria is met.
Mr. Rosenberg is the Issuer's Chief Technology Officer. The Issuer's Board of Directors identified Mr. Rosenberg as a Section 16 Reporting Person on April 12, 2018.
/s/ Morris Rosenberg
2018-05-15